Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Deferred Taxes: 2023-2024

Historic Deferred Taxes for Xeris Biopharma Holdings (XERS) over the last 2 years, with Sep 2024 value amounting to -$3.3 million.

  • Xeris Biopharma Holdings' Deferred Taxes fell 592.44% to -$3.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$3.5 million, marking a year-over-year change of. This contributed to the annual value of -$2.3 million for FY2024, which is 81.59% down from last year.
  • Xeris Biopharma Holdings' Deferred Taxes amounted to -$3.3 million in Q3 2024, which was down 543.79% from $749,000 recorded in Q2 2024.
  • In the past 5 years, Xeris Biopharma Holdings' Deferred Taxes ranged from a high of $749,000 in Q2 2024 and a low of -$3.3 million during Q3 2024.
  • Over the past 2 years, Xeris Biopharma Holdings' median Deferred Taxes value was -$184,000 (recorded in 2023), while the average stood at -$586,167.
  • Within the past 5 years, the most significant YoY rise in Xeris Biopharma Holdings' Deferred Taxes was 210.96% (2024), while the steepest drop was 592.44% (2024).
  • Over the past 2 years, Xeris Biopharma Holdings' Deferred Taxes (Quarterly) stood at -$1.2 million in 2023, then crashed by 592.44% to -$3.3 million in 2024.
  • Its last three reported values are -$3.3 million in Q3 2024, $749,000 for Q2 2024, and $307,000 during Q1 2024.